ProMIS Neurosciences Advances Alzheimer's Disease Program

ProMIS Neurosciences continues to further develop antibody candidates that have shown selectivity for the toxic forms of tau. New pre-clinical data show that these antibody candidates can block the spread of pathogenic tau aggregate formation in a cellular model. Continued advancement of ProMIS' dual approach for Alzheimer's disease, which also includes antibody PMN310 targeting the toxic oligomers of amyloid-beta, aligns with research indicating that both misfolded proteins play a major role in disease progression and represent highly validated targets for therapy.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!

ProMIS announced its tau program in May 2019 when it identified several novel antibody candidates that preferentially bind toxic forms of tau. Pre-clinical data now show that these candidates can block the formation of pathogenic tau aggregates in a cellular model. ProMIS leveraged its proprietary drug discovery and development platform to identify conformational epitopes on misfolded tau and generate, evaluate and advance tau antibody candidates, demonstrating the platform's capacity for producing high-quality antibody candidates rapidly and cost-effectively.

"The misfolded, toxic forms of tau and amyloid-beta are the two most validated targets in Alzheimer's therapy development," said Elliot Goldstein, MD, President and CEO of ProMIS Neurosciences. "While addressing Alzheimer's will require a multifactorial approach, selective targeting of misfolded, toxic forms of both tau and amyloid-beta remains one of the most promising therapeutic strategies for Alzheimer's disease. We will continue to strengthen our programs, offering the critical one-two punch needed for a disease-modifying therapy, while simultaneously seeking ways to leverage emerging biomarkers to improve the success and speed of future clinical development."

  • <<
  • >>